An experienced team and a thoughtful, research-driven investment approach create a compelling healthcare offering for investors willing to stomach some volatility. It earns Above Average People and Process ratings.
PGIM Jennison Health Sciences Fund- Class R PJHRX
- NAV / 1-Day Return 34.65 / −0.94 %
- Total Assets 1.5B
-
Adj. Expense Ratio
1.480%
- Expense Ratio 1.480%
- Distribution Fee Level Low
- Share Class Type Retirement, Small
- Category Health
- Investment Style Mid Blend
- Min. Initial Investment 0
- Status Open
- TTM Yield 0.00
- Turnover 81%
USD | NAV as of Jul 15, 2026 | 1-Day Return as of Jul 15, 2026, 12:14 AM GMT+0
Morningstar’s Analysis PJHRX
Will PJHRX outperform in the future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 52.7
|
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
|---|---|---|---|
Eli Lilly and Co | 17.35 | 241M | Healthcare |
Merck & Co Inc | 6.06 | 84M | Healthcare |
UnitedHealth Group Inc | 5.87 | 81M | Healthcare |
Thermo Fisher Scientific Inc | 4.56 | 63M | Healthcare |
argenx SE ADR | 3.56 | 49M | Healthcare |
Vertex Pharmaceuticals Inc | 3.37 | 47M | Healthcare |
Danaher Corp | 3.28 | 46M | Healthcare |
Intuitive Surgical Inc | 3.08 | 43M | Healthcare |
Lonza Group Ltd | 3.02 | 42M | Healthcare |
CVS Health Corp | 2.52 | 35M | Healthcare |
United States